- Research article
- Open Access
- Open Peer Review
Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways
© Marra et al; licensee BioMed Central Ltd. 2010
- Received: 25 November 2009
- Accepted: 7 April 2010
- Published: 7 April 2010
Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI) anchored protein expressed not only in prostate but also in pancreas and bladder cancer as shown by immunohistochemistry and mRNA analysis. It has been targeted by monoclonal antibodies in preclinical animal models and more recently in a clinical trial in prostate cancer patients. The biological role played in tumor growth is presently unknown. In this report we have characterized the contribution of PSCA expression to tumor growth.
A bladder cell line was engineered to express a doxycycline (dox) regulated shRNA against PSCA. To shed light on the PSCA biological role in tumor growth, microarray analysis was carried out as a function of PSCA expression. Expression of gene set of interest was further analyzed by qPCR
Down regulation of the PSCA expression was associated with reduced cell proliferation in vitro and in vivo. Mice bearing subcutaneous tumors showed a reduced tumor growth upon treatment with dox, which effectively induced shRNA against PSCA as revealed by GFP expression. Pathway analysis of deregulated genes suggests a statistical significant association between PSCA downregulation and activation of genes downstream of the IFNα/β receptor.
These experiments established for the first time a correlation between the level of PSCA expression and tumor growth and suggest a role of PSCA in counteracting the natural immune response.
- Green Fluorescent Protein Expression
- Control shRNA
- shRNA Expression
- Prostate Stem Cell Antigen
- Natural Immune Response
PSCA has been discovered a decade ago and has been classified as a member of the Ly-6 family of GPI-anchored cell surface proteins . It is expressed in most prostate cancer specimens, including high-grade prostatic intraepithelial neoplasia, primary androgen-dependent tumors, and hormone-refractory metastases. PSCA levels are positively correlated with Gleason grade, tumor stage, and biochemical recurrence. Its expression is also particularly elevated in bone metastasis. Finally, PSCA is strongly expressed in other malignancies, including bladder and pancreatic cancers [2–6]. Different immunotherapy approaches targeting PSCA have been tested in preclinical models including cancer vaccine, therapeutic monoclonal antibodies and antibody conjugated to toxic drugs [7–10]. More recently, a human monoclonal antibody targeting PSCA has been evaluated in a phase I clinical trial in prostate cancer patients (AACR 2006).
Little information is available regarding the biological role of PSCA. Proteins belonging to the Ly6 family are involved in cell signaling events associated with thymic lymphocyte differentiation, maturation and activation. CD59, a member of this protein family, was shown to play a role in the protection against complement mediated lysis. In addition, it was found to be expressed in tumor cells where it may play a role in evading anti cancer immune response . Deletion of PSCA gene does not appear to interfere with normal development as PSCA knockout mice are viable. Additionally, crossing of the PSCA knockout mice with prostate tumor models driven by large T antigen did not increase primary tumor formation [12, 13].
Here the biological role of human PSCA was evaluated using RNA interference and microarray analysis. To establish a pharmacologic control over gene expression a shRNA against PSCA was identified and expressed under the control of dox in a lentivirus system . Microarray analysis was utilized to identify genes coregulated with PSCA in tumor xenografts.
Cell culture and generation of lentivirus vectors
The 293T and SW780 cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. The lentivirus system for conditional gene suppression with dox-inducible shRNAs utilized has been described previously. Briefly, in the absence of dox, tTR-KRAB repressor binds to tetO and suppresses H1-mediated shRNA transcription, thus allowing normal expression of the cellular target gene. In the presence of 10 μg/ml of dox, tTR-KRAB cannot bind to tetO and hence shRNAs are produced, leading to downregulation of PSCA. The green fluorescent protein (GFP) cDNA contained in the shRNA vector provides a monitoring device, as it is switched on by dox treatment and GFPis expressed. All recombinant lentiviruses were produced by transient transfection in 293T cells. Briefly, 293T cells were cotransfected with 20 μg of pLUTHM-shPSCA3 plasmid, 15 μg of pCMV-ΔR8.91, and 5 μg of pMD2G-VSVG by calcium phosphate precipitation. After 16 h medium was changed, and recombinant lentivirus vectors were harvested 48 h later. FACS analysis was conducted as previously described .
Cell viability was monitored using the CellTiter-Blue Viability. The assay is based on the ability of living cells to convert a redox dye (resazurin) into a fluorescent end product (resorufin); 1 × 103 SW780-shPSCA and SW780-shControl cells +/- Dox were plated in a 96 well plate in parallel with the parental cell line SW780. Cells were incubated at 37°c for 96 hrs, and fluorescence was subsequently monitored using a plate-reading fluorometer.
Six-week-old female CD-1 nude mice were purchased from Charles River Laboratories and maintained in accordance to Guidelines for the Care and Use of Laboratory Animals in IRBM's animal facility. This study, was submitted and approved by the IRBM ethical committee . Mice were injected subcutaneously (sc) in the right flank with 2 × 106 SW780-shPSCA cells resuspended into 100 μL phosphate-buffered saline (PBS) and Matrigel (1:1). Mice received 5% sucrose only or 5% sucrose plus 0.2 mg/ml of dox for control and knockdown cohorts, respectively. All water bottles were changed 3 times per week. Tumors were measured with calipers and mice weighed twice per week. At the end of the dosing study, or as indicated, appropriate tumor samples were taken.
Total RNA from cell in culture was isolated with RNAzolB and then dissolved in RNase-free water. 25 μg of total RNA was treated with DNase using the Qiagen RNase-free DNase kit and RNeasy spin columns. Then RNA was dissolved in RNase-free water to a final concentration of 0.2 μg/μl. cRNA was generated using T7 RNA polymerase on 5 μg of total RNA and labeled with Cy5 or Cy3 (Cy Dye, Amersham Pharmacia Biotech). From each sample, 5 μg of labeled-RNA were co-hybridized with 5 μg of a reference RNA (pool of two untreated SW780 cell lines). Labeled cRNAs were fragmented to an average size of 50-100 nucleotides by heating the samples to 60°C with 10 mM of zinc chloride and then adding an hybridization buffer containing 1 M NaCl, 0.5% sodium sarcosine, 50 mM MES, pH6.5, and formamide to a final concentration of 30%. The final volume was 3 ml at 40°C.
Samples were hybridized on a customized Agilent 44 k array containing ~40,000 unique probes mapping to ~21,000 human genes. Each sample was hybridized in duplicate with fluor reversal to systematically correct for dye bias. After hybridization, slides were washed and scanned using a confocal laser scanner (Agilent Technologies). The raw intensities obtained after scanning were quantified, background-corrected and lowness normalized. A weighted average ratio was computed for dye-swapped pairs of hybridizations. Tumors were collected in RNA later and processed for RNA extraction as described previously . Samples were hybridized on a customized Affymetrix array containing ~38,000 probes mapping to ~21,000 human genes .
The microarray dataset was filtered before clustering in order to select the 2,000 most variable probes. probes with an absent call in more than 12 samples out of 14 were removed the 2,000 probes with the higher interquartile range were retained for subsequent analysis. Probes were hierarchically clustered using an average linkage algorithm based on Pearson correlation coefficients.
Identification of deregulated probes
Differences in average probe expression between the dox+ (PSCA silencing) and dox-samples were computed by 1-way ANOVA. Probes differentially expressed between the two classes were identified based on ANOVA p-value < 0.001.
Gene set enrichment analysis
Groups of genes identified by 1-way ANOVA were compared to a collection of annotated gene sets to identify the functional classes that were significantly over-represented. The enrichment p-values were computed according to the Fisher's exact test. The gene sets were obtained from public (Gene Ontology , KEGG , Interpro , Panther , oPOSSUM  and commercial sources (GeneGo (GeneGo Inc., St Joseph, MI, USA), Ingenuity (Ingenuity Systems Inc, Mountain View, CA, USA), TRANSFAC .
Microarray findings were confirmed by real-time reverse-transcription PCR (RT-PCR) using the average value of mRNA from dox untreated SW780-shPSCA samples as calibrator. Analysis of mRNA expression of selected IFNα genes was performed using Applied Biosystems expression kit following manufacturers' instructions. Expression values were computed using the comparative CT method (ΔΔ CT) with GAPDH gene expression value serving as normaliser.
Establishment of cell clones with inducible shRNA against PSCA
shRNA sequences against PSCA
Biological effects of PSCA down-regulation in SW780 cells
To characterize the impact of PSCA expression on cell growth, a viability assay was carried out. A statistical significant reduction in cell viability was observed in dox treated cells whereas no difference was observed in control transfected cells (Figure 1B).
Transcriptional data analysis
Genes differentially expressed upon reduction of PSCA expression and overlap between in vitro and in vivo dataset.
The genes identified as differentially expressed were analyzed by gene set enrichment analysis, using the same method also used elsewhere . In this way we could monitor the pathways showing a global transcriptional perturbation upon silencing of PSCA (Figure 3B). We defined as up- or down-regulated the pathways statistically enriched in the list of genes up- or down-regulated, respectively, in the presence or absence of treatment. A statistically significant enrichment was observed between the list of genes up-regulated upon PSCA silencing (dox+). The IFNα/β signaling pathway resulted to be up-regulated upon PSCA silencing in the in-vivo experiments but its up-regulation was not evident in the in vitro datase. Out of the 27 genes listed in the Ingenuity database for interferon signaling 12 were up-regulated in vivo and 1 in vitro, STAT2. Similar results were obtained using the GeneGo database to run the analyses (8 out of 28 genes). In addition, the "antigen presentation" pathway resulted as perturbed with the highest statistical significance. Other immune related pathways were also affected although at lower statistical significance. In agreement with the reduced cell viability in vitro (Figure 1B) and reduced tumor growth (Figure 2A) the down-regulated pathways were "growth" and "negative regulation of apoptosis".
In this study, we have identified a correlation between PSCA expression and tumor growth in vivo. High level of PSCA mRNA and protein expression has been observed in most primary prostate and pancreatic human tumors and in particular in aggressive metastatic forms. In bladder cancer, higher levels of PSCA expression correlated with increasing tumor grade  and more recently genetic variants in this gene were associated with cancer occurrence, although the biological implications of this observation remain to be elucidated.
The observed tumor specific expression of PSCA has prompted the development of therapeutic antibodies specific for this membrane protein. Indeed, growth inhibition has been observed upon antibody treatment of cells transfected with vectors expressing PSCA or of naturally expressing cell lines such as SW780. The published studies are in agreement with the data reported here indicating that reduced PSCA expression is associated with lower viability . Thus, based on these published data, a better understanding of the biologic role played by PSCA in tumor growth is warranted.
To shed light on PSCA role in tumor biology we compared PSCA expression in different cell lines and found expression on cell surface in few of them or in explanted primary tumors. Thus, the bladder cell line SW780 was engineered to obtain a pharmacological controlled expression of PSCA and to study the impact of reduced PSCA gene expression on cell viability and tumor growth. Here, we report a direct correlation between PSCA expression and tumor growth. Of note is the observation that pretreatment with dox in vitro further reduced tumor growth. This latter result may be partially explained by the slow decay of PSCA displayed on the cell membrane as indicated by FACS analysis.
A role for PSCA in tumor proliferation is further supported by the biological pathway analysis of gene expression profiling where a statistical significant association with "negative regulation of apoptosis" and "growth" was observed. Many of the pathways activated upon PSCA downregulation control key immune functions. Activation of IFNα/β signal transduction pathway was observed only in SW780-shPSCA tumors (Figure 2B) and it was not evident in tumors obtained upon injection of control cells. In contrast, similar studies conducted with these cell lines in vitro did not show induction of the pathway suggesting that in the tumor context additional factors such as those related to immune modulation may contribute to the observed microarray signature. A quantitative analysis of gene expression by qPCR confirmed overexpression of IFNα/β genes (Figure 4). The activation of IFNα/β pathway only in vivo further supports the idea that triggering of this pathway is not determined by an intracellular mechanism related to double strand RNA, as it has been previously reported. On the contrary, the data suggest that IFNα/β activation is related to environmental signals. The activation of IFNα/β pathway is consistent with a reduced tumor growth as previously shown with recombinant IFNα [27, 28] .
Nonetheless, further experiments are required to better characterize the link between PSCA downregulation and activation of immune pathways such as IFNα/β. In this direction it is worth mentioning a potential physical interaction between PSCA and IFNα/β receptor. PSCA is a GPI-anchored protein located in lipid raft. IFNα/β receptor can be brought into this subcellular compartment upon interaction with its ligands . Thus, PSCA may counteract intracellular signaling exerted by the IFNα/β receptor playing a role as a defense protein. This biological role is reminiscent of the interfering role played by PSCA homolog, CD59, in the complement system . Activation of the complement system is tightly regulated and among the various regulators CD59 has been identified as the single membrane regulator of the terminal membrane attack complex. Moreover CD59 has been characterized as a negative regulator of the T-cell response in mice. Although we limited our qPCR confirmation only to IFNα/β pathway, a statistical significant up regulation was observed also for other immune pathways such as of MHC-1 pathway. Given the pleiotropic effects of IFNα/β pathway it is likely that some pathways, including MHC-1 presentation, may be affected downstream. A more in depth analysis would be required to answer this question. Finally we cannot exclude that the correlations observed only in tumors and not in cell culture are driven by undefined factors that are not captured in the expression profile and deserve further investigation.
The current findings suggest a role of PSCA in counteracting the natural immune response against cancer. This information could help in design more effective experiments in preclinical models not only with monoclonal antibodies but also with approaches based on cancer vaccine [31–35]. It would be of interest to correlate antitumor efficacy of PSCA-targeting therapies as a function of the natural immune response.
The authors thank Aya Jakobovits and Jean Gudas for anti PSCA antibody, 4.117. The authors also thank Brendan Leeson and Ernest Coffey from Gene Expression Laboratories - Rosetta and LAR personnel for technical support. This work was partially supported by Progetto Integrato Oncologia, Ministero della Salute e Associazione Italiana per la Ricerca sul Cancro (AIRC).
- Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA. 1998, 95: 1735-1740. 10.1073/pnas.95.4.1735.View ArticlePubMedPubMed CentralGoogle Scholar
- Rodriguez JA, Li M, Yao Q, Chen C, Fisher WE: Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications. World J Surg. 2005, 29: 297-305. 10.1007/s00268-004-7843-0.View ArticlePubMedGoogle Scholar
- Elsamman E, Fukumori T, Kasai T, Nakatsuji H, Nishitani MA, Toida K, Ali N, Kanayama HO: Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int. 2006, 97: 1202-1207. 10.1111/j.1464-410X.2006.06153.x.View ArticlePubMedGoogle Scholar
- Grubbs EG, Abdel-Wahab Z, Tyler DS, Pruitt SK: Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Ann Surg Oncol. 2006, 13: 1645-1654. 10.1245/s10434-006-9029-5.View ArticlePubMedGoogle Scholar
- Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE: Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007, 30: 396-405. 10.1097/CJI.0b013e318031b53b.View ArticlePubMedGoogle Scholar
- Tanaka M, Komatsu N, Terakawa N, Yanagimoto Y, Oka M, Sasada T, Mine T, Gouhara S, Shichijo S, Okuda S, Itoh K: Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients. Oncol Rep. 2007, 18: 161-166.PubMedGoogle Scholar
- Gu Z, Yamashiro J, Kono E, Reiter RE: Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res. 2005, 65: 9495-9500. 10.1158/0008-5472.CAN-05-2086.View ArticlePubMedGoogle Scholar
- Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, et al: Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 2002, 62: 2546-2553.PubMedGoogle Scholar
- Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A: Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA. 2001, 98: 2658-2663. 10.1073/pnas.051624698.View ArticlePubMedPubMed CentralGoogle Scholar
- Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, Friess H, Buchler MW, Reiter RE, Hines OJ: Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005, 31: 119-125. 10.1097/01.mpa.0000173459.81193.4d.View ArticlePubMedGoogle Scholar
- Gorter A, Meri S: Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today. 1999, 20: 576-582. 10.1016/S0167-5699(99)01537-6.View ArticlePubMedGoogle Scholar
- Jalkut MW, Reiter RE: Role of prostate stem cell antigen in prostate cancer research. Curr Opin Urol. 2002, 12: 401-406. 10.1097/00042307-200209000-00006.View ArticlePubMedGoogle Scholar
- Moore ML, Teitell MA, Kim Y, Watabe T, Reiter RE, Witte ON, Dubey P: Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate. 2008, 68: 139-151. 10.1002/pros.20686.View ArticlePubMedGoogle Scholar
- Wiznerowicz M, Trono D: Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol. 2003, 77: 8957-8961. 10.1128/JVI.77.16.8957-8951.2003.View ArticlePubMedPubMed CentralGoogle Scholar
- Elia L, Mennuni C, Storto M, Podda S, Calvaruso F, Salucci V, Aurisicchio L, Scarito A, Ciliberto G, La Monica N, Palombo F: Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: initial identification of predictive biomarkers. Eur J Immunol. 2006, 36: 1337-1349. 10.1002/eji.200535514.View ArticlePubMedGoogle Scholar
- D'Errico M, Rinaldis ED, Blasi MF, Viti V, Falchetti M, Calcagnile A, Sera F, Saieva C, Ottini L, Palli D, et al: Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer. 2008, 45 (3): 461-9. 10.1016/j.ejca.2008.10.032.View ArticlePubMedGoogle Scholar
- Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31: e15-10.1093/nar/gng015.View ArticlePubMedPubMed CentralGoogle Scholar
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000, 25: 25-29. 10.1038/75556.View ArticlePubMedPubMed CentralGoogle Scholar
- Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28: 27-30. 10.1093/nar/28.1.27.View ArticlePubMedPubMed CentralGoogle Scholar
- Mulder NJ, Apweiler R, Attwood TK, Bairoch A, Bateman A, Binns D, Bork P, Buillard V, Cerutti L, Copley R, et al: New developments in the InterPro database. Nucleic Acids Res. 2007, 35: D224-228. 10.1093/nar/gkl841.View ArticlePubMedPubMed CentralGoogle Scholar
- Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A: PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003, 13: 2129-2141. 10.1101/gr.772403.View ArticlePubMedPubMed CentralGoogle Scholar
- Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP, Wasserman WW: oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res. 2005, 33: 3154-3164. 10.1093/nar/gki624.View ArticlePubMedPubMed CentralGoogle Scholar
- Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, et al: TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003, 31: 374-378. 10.1093/nar/gkg108.View ArticlePubMedPubMed CentralGoogle Scholar
- Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, Palombo F, Viti V, Mesiti G, Zappulli V, et al: Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics. 2009, 10: 135-10.1186/1471-2164-10-135.View ArticlePubMedPubMed CentralGoogle Scholar
- Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, Dorey F, Said J, Reiter RE: Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 2001, 61: 4660-4665.PubMedGoogle Scholar
- Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, et al: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 2009, 41: 991-995. 10.1038/ng.421.View ArticlePubMedPubMed CentralGoogle Scholar
- Rosebeck S, Leaman DW: Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a. Apoptosis. 2008, 13: 562-572. 10.1007/s10495-008-0190-0.View ArticlePubMedGoogle Scholar
- Santodonato L, Ferrantini M, Palombo F, Aurisicchio L, Delmastro P, La Monica N, Di Marco S, Ciliberto G, Du MX, Taylor MW, Belardelli F: Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Ther. 2001, 8: 63-72. 10.1038/sj.cgt.7700274.View ArticlePubMedGoogle Scholar
- Claudinon J, Monier MN, Lamaze C: Interfering with interferon receptor sorting and trafficking: impact on signaling. Biochimie. 2007, 89: 735-743. 10.1016/j.biochi.2007.03.014.View ArticlePubMedGoogle Scholar
- Kimberley FC, Sivasankar B, Paul Morgan B: Alternative roles for CD59. Mol Immunol. 2007, 44: 73-81. 10.1016/j.molimm.2006.06.019.View ArticlePubMedGoogle Scholar
- Dannull J, Diener PA, Prikler L, Furstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M: Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 2000, 60: 5522-5528.PubMedGoogle Scholar
- Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H: Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer. 2006, 119: 2428-2434. 10.1002/ijc.22097.View ArticlePubMedGoogle Scholar
- Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, Bachmann M, Abken H, Rieber EP, Temme A: Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 2007, 67: 1121-1131. 10.1002/pros.20608.View ArticlePubMedGoogle Scholar
- Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W: Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. J Gene Med. 2007, 9: 715-726. 10.1002/jgm.1067.View ArticlePubMedGoogle Scholar
- Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM: Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008, 68: 861-869. 10.1158/0008-5472.CAN-07-0445.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/10/129/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.